Ponesimod clinical trials
Also written ACT-128800.
How each study uses ponesimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ponesimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Mar 2021 · PONVORY · NDA 213498 (FDA, Drugs@FDA)
- European Union
- 19 May 2021 · Ponvory · EMEA/H/C/005163 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 0
Actelion (13) · Vanda Pharmaceuticals (2) · Janssen Pharmaceutica N.V., Belgium (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ponesimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisRecruitingPhase 3Vanda PharmaceuticalsNCT07362017Written as Ponesimod
- Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Vanda PharmaceuticalsNCT07686081Written as Ponesimod
- Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisCompletedPhase 3ActelionNCT03232073Written as Ponesimod
- A Study of Ponesimod in Healthy Adult ParticipantsCompletedPhase 1Janssen Pharmaceutica N.V., BelgiumNCT05552196Written as Ponesimod
- Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisCompletedPhase 2ActelionNCT01006265Written as ACT-128800 Dose 1
- Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisCompletedPhase 2ActelionNCT01093326Written as Ponesimod 10 mg
- Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisCompletedPhase 3ActelionNCT02425644Written as ponesimod
- ACT-128800 in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 2ActelionNCT01208090Written as ACT-128800
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHDTerminatedPhase 2ActelionNCT02461134Written as Ponesimod
- Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)TerminatedPhase 3ActelionNCT02907177Written as Ponesimod
- Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male SubjectsCompletedPhase 1ActelionNCT02068235Written as Ponesimod 5mg i.v.
- Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female SubjectsCompletedPhase 1ActelionNCT02223832Written as ACT-128800
- Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female SubjectsCompletedPhase 1ActelionNCT02136888Written as Ponesimod 10 mg
- Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male SubjectsCompletedPhase 1ActelionNCT02126956Written as ACT-128800
- Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy SubjectsCompletedPhase 1ActelionNCT02029482Written as ACT-128800
- ACT-128800 in PsoriasisCompletedPhase 2ActelionNCT00852670Written as ACT-128800
Codes
What other systems call ponesimod · ClinicalTrials.gg INT005646
- MeSH (NLM) C550169ponesimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5G7AKV2MKPPONESIMODConfirmed FDA, NLM
- RxNorm 2532300One source FDA
- NCI Thesaurus C96534PonesimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C550169 | ponesimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5G7AKV2MKP | PONESIMOD | Confirmed FDA, NLM |
| RxNorm | 2532300 | — | One source FDA |
| NCI Thesaurus | C96534 | Ponesimod | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.